Drug
Apatinib mesylate tablet
Apatinib mesylate tablet is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Other(3)
Detailed Status
unknown3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed125%
unknown375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04350190
unknownphase_2
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
NCT03612219
unknownphase_2
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
NCT03130270
unknownphase_2
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
NCT02995187
Clinical Trials (4)
Showing 4 of 4 trials
NCT04350190Phase 2
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT03612219Phase 2
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
NCT03130270Phase 2
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
NCT02995187Phase 2
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4